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Background: Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was
significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with
mild to severe plaque psoriasis.
Objective: To assess long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof.
Methods: Patients completing the 12-week trials were eligible for 40-weeks’ open-label treatment and
4-weeks’ follow-up. Treatment was based on the Physician Global Assessment (PGA) score. Patients
entering with PGA$1 received tapinarof until PGA = 0. Patients with PGA = 0 discontinued tapinarof and
were monitored for remittive effect. Patients with PGA$2 were re-treated until PGA = 0.
Results: Overall, 91.6% (n = 763) of eligible patients enrolled; 40.9% of patients achieved complete disease
clearance (PGA = 0), and 58.2% entering with PGA$2 achieved PGA = 0 or 1. Mean duration of off therapy remittive
effect for patients achieving PGA = 0 was 130.1 days. No new safety signals were observed. Most frequent adverse
events were folliculitis (22.7%), contact dermatitis (5.5%), and upper respiratory tract infection (4.7%).
Limitations: Open-label; no control; may not be generalizable to all forms of psoriasis; remittive effect/
response rate potentially underestimated.
Conclusions: Efficacy improved beyond the 12-week trials, with a 40.9% complete disease clearance rate,
;4-month off therapy remittive effect, durability on therapy, and consistent safety. ( J Am Acad Dermatol
2022;87:800-6.)
Key words: plaque psoriasis; PSOARING 3 trial; remittive effect; tapinarof; therapeutic aryl hydrocarbon
receptor (AhR)-modulating agent.

From the Department of Dermatology, Yale University, New
Haven, Connecticuta; Central Connecticut Dermatology
Research, Cromwell, Connecticutb; Department of Dermatology, Henry Ford Health System, Detroit, Michiganc; Department of Dermatology Research, Innovaderm Research Inc,
Montreal, Quebec, Canadad; Department of Clinical Research,
Keck School of Medicine University of Southern California, Los
Angeles, Californiae; Department of Dermatology, Icahn School
of Medicine, Mount Sinai, New York, New Yorkf; Department of
Dermatology, Skin Sciences, PLLC, Louisville, Kentuckyg;
Department of Dermatology, University of Texas Health Science
Center, Houston, Texash; and Dermavant Sciences, Inc, Morrisville, North Carolina.i
Funding sources: Supported by Dermavant Sciences, Inc. Medical
writing and editorial assistance were funded by Dermavant
Sciences, Inc.
IRB approval status: The study protocol, the informed consent, and
other information that required preapproval were reviewed

800

and approved by an Institutional Review Board (IRB) in
accordance with the International Council for Harmonisation
(ICH) Good Clinical Practice (GCP) and applicable country-specific requirements including United States 21 Code of Federal
Regulations (CFR) 312, subpart D for constitution of independent ethics committees.
Accepted for publication June 5, 2022.
Reprints not available from the authors.
Correspondence to: Bruce Strober, MD, PhD, Yale University, New
Haven, CT 06510 & Central Connecticut Dermatology Research,
Cromwell, CT 06416. E-mail: brucestrober30@me.com.
Published online June 27, 2022.
0190-9622
Ó 2022 by the American Academy of Dermatology, Inc. Published
by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.jaad.2022.06.1171

J AM ACAD DERMATOL

Strober et al 801

VOLUME 87, NUMBER 4

INTRODUCTION

Canada) extension trial of tapinarof cream 1%
QD in adults with mild to severe plaque
Topical therapies remain the mainstay for most
psoriasis.
patients with psoriasis across the spectrum of disease
severity.1 Existing topicals are efficacious and are
routinely used alone and in combination therapy,2-4
METHODS
but most have restrictions on duration, extent, and
Trial design
sites of application due to potential adverse events
PSOARING 3 assessed the safety, efficacy, tolera(AEs).1 Although controversial, tachyphylaxis (loss of
bility, durability of response on therapy (absence of
effectiveness) is often reported after extended use of
tachyphylaxis), and duration of remittive effect off
corticosteroids ([12 weeks).4
therapy of tapinarof cream
Furthermore, psoriasis can
1% QD. Patients with plaque
CAPSULE SUMMARY
recur after cessation of
psoriasis received up to
therapy, including corticoste40 weeks of open-label treatTapinarof cream 1% once daily was safe,
roids or biologics.4,5 No topiment, followed by 4-weeks’
well tolerated, and durably efficacious in
cals with novel mechanisms of
off treatment follow-up
patients with mild to severe psoriasis for
action had been approved by
(Supplementary Fig 1, availup to 1 year, with 40.9% complete
the
Food
and
Drug
able via Mendeley at https://
disease clearance rate, ;4-month
Administration (FDA) for
doi.org/10.17632/
remittive effect, and no tachyphylaxis.
over 25 years, highlighting a
sgdn2s5yfc.2). Patients could
need for efficacious topical
Tapinarof may represent a novel
receive tapinarof for up to
therapies
that
address
nonsteroidal topical therapy that
52 weeks from PSOARING 1
these limitations.1,4 Tapinarof
addresses limitations of current
and 2 baseline through
(VTAMAÒ;
Dermavant
therapies.
PSOARING 3 completion.
Sciences, Inc) is a novel, firstThe trial was conducted
in-class,
small-molecule
according to Good Clinical
topical therapeutic aryl hydrocarbon receptor (AhR)
Practice and the Declaration of Helsinki. Approval
agonist, FDA approved for the treatment of psoriasis6
was obtained from local ethics committees/instituand under investigation for atopic dermatitis.1
tional review boards at each center. All patients
Tapinarof specifically binds and activates AhR, a
provided written informed consent.
ligand-dependent transcription factor that downregulates proinflammatory cytokines, including interTrial participants
leukin (IL)-17A and IL-17F, normalizes skin barrier
In PSOARING 3, eligible patients had completed
protein expression, and increases antioxidant activ1
12-weeks
treatment with tapinarof or vehicle in
ity. In a phase 2 trial, tapinarof cream 1% demonPSOARING
1 or 2 before enrolling. Patients were
strated limited systemic exposure under maximal-use
aged
18e75
years with chronic plaque psoriasis,
conditions in patients with extensive psoriasis, up to
were
stable
for
at least 6 months before randomiza46% body surface area (%BSA) affected, indicating
tion,
had
%BSA
affected of $3% and #20%
low potential for systemic AEs following topical
7
(excluding
scalp,
palms,
soles, fingernails, toenails),
application. In 2 identically designed, phase 3, ranand
had
the
Physician
Global Assessment (PGA)
domized, double-blind, vehicle-controlled, multiscore
of
2
(mild),
3
(moderate),
or 4 (severe) at
center trials (PSOARING 1 and 2), tapinarof cream
screening.
Full
inclusion
and
exclusion
criteria, pre1% once daily (QD) demonstrated clinically meaningviously
reported
for
PSOARING
1
and
2,8 are proful and statistically significant efficacy over 12 weeks
vided in Supplementary Table I, available via
in adults with mild to severe plaque psoriasis.8 All
Mendeley at https://doi.org/10.17632/sgdn2s5yfc.2.
primary and secondary endpoints were achieved with
statistical significance and clinically meaningful improvements. In addition, tapinarof significantly and
Trial treatment
consistently improved patient-reported outcomes.9
In PSOARING 3, patients were treated based on
Furthermore, a remittive effect warranting further
their PGA score. Patients entering the trial having
investigation was observed in a 12-week phase 2b
achieved complete disease clearance (PGA = 0
trial, where efficacy was maintained for 4 weeks after
[clear]) after the 12-week pivotal trials discontinued
discontinuation of tapinarof.10
treatment and were monitored for remittive effect,
Here, we report the results of PSOARING 3,
defined as maintenance of PGA score of 0 (clear) or 1
the long-term, open-label, multicenter (US,
(almost clear) while off therapy.
d

d
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Abbreviations used:
AE:
AhR:
BSA:
IL:
PASI:
PGA:

adverse events
aryl hydrocarbon receptor
body surface area
interleukin
Psoriasis Area and Severity Index
Physician Global Assessment

Patients entering with PGA$1 were instructed to
apply a thin layer of tapinarof 1% QD to all affected
areas, including newly appearing lesions. During
trial visits, patients applied tapinarof under supervision. Visits occurred every 4 weeks with a follow-up
visit at Week 44 or 4 weeks after the last visit. Patients
entering with, or achieving, PGA = 0 discontinued
treatment and were observed for off-therapy remittive effect. If disease worsening occurred, defined as
PGA$2, tapinarof was restarted and continued until
PGA = 0. This pattern of treatment, discontinuation
upon PGA = 0, and retreatment continued until trial
end. Therefore, patients could receive tapinarof
continuously or intermittently.
Adherence was evaluated based on patient diaries
and weight of tapinarof tubes used; the actual
number of doses administered was compared with
expected exposure. Patients were permitted, but not
required, to treat fingernail, toenail, palm, sole, and
scalp lesions; however, these areas were not assessed for efficacy.
Outcome measures and statistical analysis
Safety. Safety and tolerability assessments
included incidence and frequency of AEs, patientand investigator-assessed local tolerability, vital
signs, physical examinations, and laboratory tests.
AEs were assessed using Common Terminology
Criteria for Adverse Events, version 5.0, where grade
1 corresponds to ‘‘mild’’ and grade 5 to ‘‘fatal.’’ AEs of
special interest based on previous trials were folliculitis, contact dermatitis, and headache.8,10,11 Local
tolerability was evaluated using a patient-reported
5-point scale of 0 (none) to 4 (strong/severe) for
burning/stinging and itching and an investigatorassessed 5-point scale of 0 (no irritation) to 4 (very
severe) for dryness, erythema, and peeling.
Efficacy. Efficacy endpoints included: the proportion of patients achieving complete disease
clearance (PGA = 0) at any time during the trial; the
total duration of remittive effect during the 44-week
trial, defined as duration of efficacy maintenance
(PGA = 0 or 1) while off therapy; the median duration
of remittive effect in patients entering with PGA = 0;
and the proportion of patients entering the trial with
PGA$2 who achieved a response, defined as
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PGA = 0 or 1 at any time during the trial. Due to
the intermittent treatment regimen, patients could
achieve PGA = 0 or a response more than once
during the trial. Durability of response (absence of
tachyphylaxis) with intermittent treatment over time
was evaluated using independent measures of
response while on treatment, including PGA score,
%BSA, and Psoriasis Area and Severity Index (PASI)
over the 40-week treatment period. PASI and %
BSA assessments were modified, as patients were
permitted, but not required, to treat fingernail,
toenail, palm, sole, and scalp lesions; however,
PASI and %BSA analyses did not include assessment
of psoriasis in these areas.
Statistical analyses. Sample size was based on
the International Council for Harmonization’s E1
guideline on the extent of population exposure to
assess clinical safety for drugs for long-term
treatment of non-life-threatening conditions.12
Approximately 850 patients were planned to be
enrolled. Efficacy endpoints were summarized
descriptively using observed cases and last observation carried forward in the intention-to-treat population. The time-to-event parameters were
summarized using the Kaplan-Meier (KM) product
limit method, using observed cases. Safety assessments were summarized descriptively in the intention-to-treat population.

RESULTS
Patient disposition and baseline
characteristics
Of 833 eligible patients from PSOARING 1 and 2,
763 (91.6%) elected to enroll in PSOARING 3.
Supplementary Table II, available via Mendeley at
https://doi.org/10.17632/sgdn2s5yfc.2 reports patient disposition in PSOARING 3. At PSOARING 3
baseline, the mean age was 50.7 years, 58.7% were
male, and 84.3% were White. At baseline, 10.4% of
patients had PGA = 0, 21.1% had PGA = 1, 32.4% had
PGA = 2, 32.6% had PGA = 3, and 3.0% had PGA = 4.
Patients previously treated with tapinarof had lower
baseline PGA scores than those treated with vehicle,
reflecting the significant efficacy of tapinarof in the
pivotal trials.
Mean %BSA was 4.7%, and the mean PASI was 4.8.
Baseline disease characteristics are summarized in
Supplementary Table III, available via Mendeley at
https://doi.org/10.17632/sgdn2s5yfc.2, including by
prior treatment in the pivotal trials. Baseline disease
scores were lower in patients previously treated with
tapinarof than in those treated with vehicle. Mean
baseline %BSA was 3.3% in patients previously
treated with tapinarof and 7.3% in patients previously treated with vehicle. At baseline, 42.9% of
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patients previously treated with tapinarof had
PGA = 0 or 1 compared with 8.6% of those who
had received vehicle.
Safety, tolerability, and adherence
AEs were consistent with previous trials,8,10 with
no new safety signals identified during long-term
treatment (Supplementary Table IV, available via
Mendeley at https://doi.org/10.17632/sgdn2s5yfc.
2). The most frequent treatment-emergent AEs
included folliculitis (22.7%), contact dermatitis
(5.5%), and upper respiratory tract infection (4.7%).
The incidence and severity of folliculitis and contact
dermatitis neither increased nor worsened with longterm treatment compared with the pivotal trials, and
most of these AEs were mild or moderate. Trial
discontinuation rates due to folliculitis or contact
dermatitis were low (1.2% and 1.4%, respectively)
and were similar to rates observed in the pivotal
trials.8
Investigators assessed that [90% of patients had
no irritation (score of 0) at all visits over the 40-week
trial. Favorable tolerability was also demonstrated
when tapinarof was applied on sensitive and intertriginous skin (Supplementary Fig 2, available via
Mendeley at https://doi.org/10.17632/sgdn2s5yfc.
2). Patient-reported burning/stinging and itching
were rated as low (none, slight, or mild) by 86% to
92% of patients over 40 weeks. The number of doses
administered compared with expected exposure
(adherence) was approximately 90%.
Efficacy
Complete disease clearance (PGA 5 0). At
baseline, 10.4% (79/763) of patients had PGA = 0
(14.6% [74/508] of patients previously treated with
tapinarof; 2.0% [5/255] of patients previously treated
with vehicle). Overall, 40.9% (312/763) achieved
complete disease clearance (PGA = 0) at least once
during the trial. For patients entering with PGA$1,
34.3% (233/680) achieved PGA = 0 at least once.
Response. In PSOARING 3, continued efficacy
was observed with tapinarof 1% QD beyond that
seen in the pivotal trials, indicating that maximal
effect may not have been achieved by Week 12 in
PSOARING 1 and 2. Overall, 58.2% (302/519) of
patients entering PSOARING 3 with PGA$2
achieved PGA = 0 or 1 at least once during the trial.
Durability of response on therapy (no tachyphylaxis)
was demonstrated for up to 52 weeks across the
trials. With intermittent use of tapinarof, the
proportion of patients achieving a PGA = 0 or 1
was consistent over time (Supplementary Fig 3,
available via Mendeley at https://doi.org/10.17632/
sgdn2s5yfc.2), with continued improvements in %

BSA and PASI also observed (Supplementary Fig 4,
available via Mendeley at https://doi.org/10.17632/
sgdn2s5yfc.2). Patients previously randomized to
vehicle in PSOARING 1 or 2 achieved similar responses in PSOARING 3 to those previously randomized to tapinarof.
PGA score by visit. In PSOARING 1 and 2, most
tapinarof-treated patients (74.5-80.3%) achieved at
least a 1-grade improvement in PGA score compared
with 30.6-35.6% of vehicle-treated patients. In
PSOARING 3, 73.3% of patients previously treated
with vehicle achieved at least a 1-grade improvement
in PGA score.
Remittive effect (duration of efficacy maintenance while off therapy). For the 79 patients
entering PSOARING 3 with PGA = 0, the median
duration of off-therapy remittive effect was 115 days
(KM estimate; 95% confidence intervals, 85.0; 168.0)
(Fig 1). The 25th and 75th KM-estimated percentiles
were 57 and 222 days, respectively, indicating that
75% of patients entering the trial with PGA = 0 were
likely to maintain efficacy off therapy for at least
57 days, while 25% of patients entering with PGA = 0
were likely to maintain efficacy off therapy for at least
222 days. Among patients entering PSOARING 3 with
PGA = 0, 24.1% (19/79) did not require retreatment.
Among patients achieving PGA = 0 at any time
during the trial (n = 312), the total duration of
remittive effect off therapy was approximately
4 months (mean: 130.1 days [SD: 89.4]). For patients
entering the trial with PGA = 0 (n = 79), the total
duration of remittive effect was 188.3 (92.8) days. For
patients entering the trial with PGA = 1 and achieving
PGA = 0 at any time during the trial (n = 88), the total
duration of remittive effect was 134.1 (86.5) days.
Clinical images of tapinarof-treated patients across
the pivotal trials and PSOARING 3 demonstrate an
off-therapy remittive effect that persisted for
24 weeks during PSOARING 3 (Fig 2;
Supplementary Fig 5, available via Mendeley at
https://doi.org/10.17632/sgdn2s5yfc.2).

DISCUSSION
In PSOARING 3, tapinarof cream 1% QD demonstrated continued improvement in efficacy beyond
that observed in the pivotal trials and was well
tolerated with long-term use of up to 52 weeks. A
high rate of complete disease clearance (40.9%),
durability of response over time, and a remittive
effect of ;4 months off therapy were demonstrated.
Tachyphylaxis, which has been reported with topical
corticosteroids and biologics,4,13,14 was not observed
with tapinarof for up to 52 weeks. The findings were
consistent with those of previous phase 2 and 3
trials.7,8,10
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Fig 1. Duration of remittive effect among patients entering PSOARING 3 with a PGA score of
0 (clear): Maintenance of a PGA of 0 or 1 (almost clear) while off therapy. Intention-to-treat
population, observed cases. *Duration of remittive effect defined as the duration of efficacy
maintenance (PGA = 0 or 1) while off therapy (patients with disease worsening [PGA$2] were
retreated with tapinarof 1% QD until PGA = 0 was achieved). yTapinarof/tapinarof, patients
previously assigned to tapinarof in the pivotal trials who received tapinarof in PSOARING 3
based on PGA score; Vehicle/tapinarof, patients previously assigned to vehicle in the pivotal
trials who received tapinarof in PSOARING 3 based on PGA score. For the total number of
patients who entered with, or achieved, a PGA of 0 at any time during the trial (n = 312), the
mean total duration of remittive effect while off therapy was 130.1 days. PGA, Physician Global
Assessment; QD, once daily.

Fig 2. Clinical response, remittive effect, and durability in a patient with plaque psoriasis
treated with tapinarof cream 1% QD: representative target lesions on a patient’s torso. PGA and
PASI are global efficacy assessments. Examples of representative target lesions of 1 tapinaroftreated patient from PSOARING 1 and 3 trials. Individual results may vary. *PSOARING 3 (LTE)
Week 24: Off treatment for 12 weeks. Patient achieved PGA = 0 at Week 12 and tapinarof
treatment was discontinued. yPSOARING 3 (LTE) Week 36: Off treatment for 24 weeks; retreatment at PSOARING 3 (LTE) Week 36 due to disease worsening. LTE, Long-term extension;
PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily.
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The mechanism for the remittive effect with
tapinarof may be explained by its specific binding
and activation of AhR, a ligand-dependent transcription factor.1 AhR activation has been shown to inhibit
T-cell expansion and T helper 17 (Th17) cell differentiation and reduce IL-17 production in T-cell
assays.15 Ligand-dependent AhR activation has
also been demonstrated to result in epigenetic
modification of both the forkhead box P3 (FoxP3)
and IL-17 gene promoters, leading to preferential
differentiation of regulatory T cells and inhibition of
Th17 cells.16 Long-term persistence of tissue-resident
memory T cells has also been shown to be AhR
dependent,17 and the remittive effect observed with
tapinarof may additionally result from reduction in
activity of these cells.18
With long-term treatment of up to 52-weeks
duration, the incidence and severity of AEs, particularly folliculitis and contact dermatitis, were consistent with that previously reported in the 12-week
pivotal trials and led to low trial discontinuation
rates. Folliculitis was generally mild, with no severe
events reported, leading to trial discontinuation in
1.2% of patients. Contact dermatitis was generally
mild or moderate, with no severe events, leading to
trial discontinuation in 1.4% of patients. Headache
was reported with low frequency, with no trial
discontinuations. Both patients and investigators
reported a favorable local tolerability profile, even
when tapinarof was applied to sensitive and intertriginous skin areas.
To characterize the long-term impact of tapinarof
and provide real-world evidence on disease management, PSOARING 3 employed a unique forcedwithdrawal design that resulted in intermittent treatment (treatment withdrawal when patients achieved
PGA = 0). The forced-withdrawal design of this trial
may have led to undertreatment, underestimating
the percentage of patients who could have achieved
a PGA of 0 or 1 at Week 40, had they received
continuous treatment. Furthermore, right censoring
of data may have resulted in underestimation of the
duration of off-therapy remittive effect because trial
end, rather than disease worsening, curtailed the
duration of evaluation for some patients.
Other trial limitations include the open-label
design and lack of a control group. As is possible
with all extension trials, patients who opted to enroll
might represent a self-selected, enriched population,
with improved response and tolerability to treatment. Finally, while this trial assessed adults with
mild to severe plaque psoriasis based on the PGA
score, patients with %BSA \3% or [20% were
excluded, and the results may not be generalizable
to all forms or severities of psoriasis, or to children. A

separate phase 3 trial (NCT05172726) evaluates
tapinarof in children.
In summary, continuous and intermittent use of
tapinarof cream 1% QD was safe and efficacious for
up to 1 year in patients with mild to severe psoriasis.
Durable efficacy on therapy and a substantial remittive effect of at least 4 months off therapy were
demonstrated. Consequently, tapinarof cream 1%
QD may represent a novel, nonsteroidal topical
therapy for patients with plaque psoriasis that is
effective and well tolerated with long-term use.
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